Elite in Mastectomy

Dr. Thomas B. Julian

General Surgery
320 E North Ave, 
Pittsburgh, PA 
Elite in Mastectomy
320 E North Ave, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Thomas Julian is a General Surgeon in Pittsburgh, Pennsylvania. Dr. Julian is rated as an Elite provider by MediFind in Mastectomy. His top areas of expertise are Breast Cancer, Lymphedema, Angiosarcoma, Menopause, and Mastectomy.

His clinical research consists of co-authoring 58 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 30 articles in the study of Mastectomy.

Specialties
General Surgery
Licenses
Surgery in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

UPMC
  • EPO
  • PPO

Locations

320 E North Ave, Pittsburgh, PA 15212

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
NSABP Biospecimen Discovery Project
NSABP Biospecimen Discovery Project
Enrollment Status: Unknown
Publish Date: October 05, 2021
Intervention Type: Biological, Drug
View 8 Less Clinical Trials

58 Total Publications

NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer.
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer.
Journal: Future oncology (London, England)
Published: June 27, 2025
Similar Doctors
Suzanne B. Coopey
Elite in Mastectomy
Dr. Suzanne B. Coopey
General Surgery
Elite in Mastectomy
Dr. Suzanne B. Coopey
General Surgery

Allegheny Clinic

4800 Friendship Ave, 
Pittsburgh, PA 
 (3.0 miles away)
Languages Spoken:
English
See accepted insurances

Suzanne Coopey is a General Surgeon in Pittsburgh, Pennsylvania. Dr. Coopey is rated as a Distinguished provider by MediFind in Mastectomy. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Mastectomy.

Elite in Mastectomy
Dr. Norman Wolmark
General Surgery
Elite in Mastectomy
Dr. Norman Wolmark
General Surgery

Magee-Women's Surgical Associates-Magee

300 Halket Street, Suite 2601, 
Pittsburgh, PA 
 (2.7 miles away)
412-438-2317
Languages Spoken:
English
See accepted insurances

Norman Wolmark is a General Surgeon in Pittsburgh, Pennsylvania. Dr. Wolmark is rated as a Distinguished provider by MediFind in Mastectomy. His top areas of expertise are Breast Cancer, Colorectal Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, and Mastectomy.

Atilla Soran
Distinguished in Mastectomy
Dr. Atilla Soran
General Surgery
Distinguished in Mastectomy
Dr. Atilla Soran
General Surgery

UPMC Magee-Womens Surgical Associates

8000 Cranberry Springs Drive, Suite 2M600, 
Cranberry Twp, PA 
 (18.3 miles away)
412-438-2621
Languages Spoken:
English, Turkish
See accepted insurances
Accepting New Patients

Atilla Soran, MD, MPH, FACS, FNCBC, is a breast surgical oncologist at Magee-Womens Hospital of UPMC. He specialized in surgical oncology, breast oncology, benign breast lesions, and lymphedema. Dr. Soran is board-certified in general surgery and received a medical degree from the University of Ankara, Ankara, Turkey. He completed residencies at St Mary's Hospital, London, England and Ankara Numune Teaching & Research Hospital, Ankara, Turkey, and a fellowship at the University of Pittsburgh School of Medicine. Dr. Soran is rated as a Distinguished provider by MediFind in Mastectomy. His top areas of expertise are Lymphedema, Breast Cancer, Intraductal Papilloma, Primary Intestinal Lymphangiectasia, and Mastectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Julian's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile